Everyone, my name is Maury Raycroft, and I'm one of the biotech analyst at Jefferies. I'd like to welcome Ron Cooper, the CEO of enGene Therapeutics. Thanks so much for joining us today, Ron.
Maury, it's really great to be here. Really appreciate the invitation.
We're going to do fireside chat format, so maybe for those who are new to this story, if you can give a brief intro to the company.
enGene Therapeutics is a non-viral plasmid-based gene therapy company. Our approach is to work in bladder cancer, particularly non-muscle invasive bladder cancer. Our lead asset is detalimogene voraplasmid, where we have pretty much completed our pivotal study. That pivotal study will be filed by the end of this year, so we'll begin the BLA process. We expect to have feedback from the FDA on accepting that early next year. By the end of next year, we expect an approval, then in 2028, a J-code. In between that, we have another cohort of patients in this non-muscle invasive bladder cancer space where we use a surfactant bladder rinse to kind of rinse the inside of the bladder before using the medicine, which is used with other viral gene therapies.
Mid-next year, we'll provide a little peek to that data, and somewhere down the line. There'll be a supplementary filing. To me, it's a pretty exciting time for the company, but I'd also say it's a really exciting time within the bladder cancer space in particular, because with the advent of new agents, it's an opportunity for patients to have sequences of these agents and keep their bladders. Folks don't like radical cystectomy, so this is a growing market. Detalimogene is an attractive product. It's the only non-viral plasmid gene therapy, and it should really fit nicely in the sequencing that's going to continue to grow.
Got it. Yeah, it's a great intro, and you did have the data update last week, and so plenty to talk about with that. I think with the 12-month landmark CR rate increasing from approximately 13% in 98 patients to 24% out of 110 patients, or with 26 CRs, can you clarify if the additional 13 CRs are all newly matured assessments or any reclassifications or something else?
Yeah, no, so exactly. We provided a data update in the middle of this year. Then we provided another one recently. I think from our perspective, I think the market overreacted to our earlier data update. The primary endpoint is CR rate at any time. We reported 54%. Now that's moved up to 56%. The key secondary endpoint is those percentage of patients that are still durable a year and beyond, and that we had a Kaplan-Meier curve of about 25. That's moved to 43. Then the third parameter, the one you were referring to, was the landmark number, 12-month landmark. That's a number which actually is not in the label. It's not a promotable number, so it's an interesting measure of durability. We had 13%, and that moved up to 24%.
The last durability number, which is really important, is the median duration, and that moved from 8.6 - 10.1 months, with a confidence interval lower bound of 7.5. The upper is still not found as yet, so we can't even evaluate that. If you kind of put that together in a package that demonstrates that we have efficacy and we have durability, our efficacy and durability are in the range of approved products. All of that, the only thing that's really happened is time. It's really data that's matured from our update in May, and our May timeframe, we had said we had 21 patients that could still have a CR over time, and that's been the case.
Got it. Yeah, that makes sense. About six of the 67 CRs occurred after the initial assessment. How does the durability of these late or re-induction responses compare with initial responses, and how much do they contribute to the greater than 12-month DOR estimate?
I think the thing that's great about detalimogene from a patient perspective and a value offering is that the CR rate is measured at the three-month and the six-month, and you're speaking about the few patients that respond at the six-month time. 91% of the patients respond at the three-month timeframe, which is actually great. If you're starting a patient, you know the majority of the patients, it's going to work usually in the first three-month timeframe. If it does work, 100% of the patients that make it into maintenance are durable. That's terrific. If it doesn't work, only 3% of them will progress. In this, remember, in this disease, recurrence is quite common. Even in the most potent product out there, 50% of the patients need something new in a year. Recurrence is common, but progression is not very common.
In our case, 91% in the first three months, good durability if you get it to maintenance. If it doesn't work, 3% may progress. For the patients that don't respond at the first cycle at three months and they respond at six months, that's so few, it really doesn't have a huge impact on our overall numbers.
Got it. Makes sense. In April, you reported CR rates of 43% at six months and then close to 33% at nine months. When are you planning to share the updated three, six, and nine-month landmark rates, and what do they show about the attrition curve?
Yeah, so they're not really as relevant numbers now, to be honest, right? Because when you think about the product label, the product label number one thing is complete response at any time, which we have. The next one is the durability. After 12 months, what percentage of those patients are responders? That goes in the label, and the median duration goes in the label. The durability number, we have nine more patients to go. So that, we're very focused on the label and getting approval. For all of these products, they start off higher, and there's attrition over time. So you kind of know where we started, and you know where we've ended. The data that you're speaking about, that's likely going to be in a medical conference somewhere down the line or in the publications. Not as important towards our filing and our planned commercialization launch.
Got it. Okay. Makes sense. For showing additional detailed data, I guess, is there a forum next year where you're aiming for that?
Well, the nice thing about it is our dataset in NMIBC at 125 patients, it's actually one of the largest datasets, and we have a real opportunity to slice and dice that and present that at multiple medical conferences. That being said, the focus right now is finalizing the BLA. Getting the BLA in by the end of this year, and making sure we fulfill the FDA expectations. So you'll see that data in medical conferences for many years to come.
Yeah.
Some really interesting data, because in particular, some of the earlier studies were done in a different era. You look at our study, it's a highly experienced patient population. 40% of the patients have CIS plus papillary, 26% of the patients have had other medicines. And so what our clinicians are saying, the key opinion leaders are saying, this is a real-life dataset, so very relevant to what's happening now. So lots of publications and presentations to come.
Got it. Okay. In May, the final 32 enrolled patients had a 39% CR rate at any time and a 32% six-month CR rate, and you initiated a root cause review. What did that review find, and how have those patients performed with additional follow-up, and how many of the five exclusions came from that group?
Yeah. Again, looking at subgroups within the total 125, right now we are not doing that any longer, because that is not the way the FDA looks at it. The FDA looks at the totality of here is the whole database, right? I think what is more important to us, we really had a pre-BLA meeting with the FDA this quarter, and we aligned on multiple things, right? Administrative issues, clinical issues, and manufacturing issues. On the administrative part, they gave us feedback, the data was sufficient for us to be eligible to initiate the filing by the end of the year. Felt very good about that. On the clinical part, to answer your question here, what is important now is we had 125 patients that were in the study. We got agreement with the FDA on the most important aspects of the statistical analysis plan.
That means five patients will be removed. The database that will form our label will be, when we submit it, will be 120 patients. The last thing we aligned on was manufacturing issues, which is, as you know, has plagued this category and delayed a lot of approvals and launch. The FDA gave us CDRP, one of nine companies gets this. What effectively that means is rather than throwing over the Module 3, the manufacturing module, over the fence and crossing your fingers, we have been in dialogue with them for quite some time now, and they have actually seen a lot of the data. In our pre-BLA meeting, we were able to cover a couple of issues that they were waiting on us on.
As a result, I think the FDA gave us that feedback to say, "This is a fileable package," and we were eligible to initiate the filing.
Got it. Makes sense. Clarifying on that point around the number of patients, did FDA agree that 120 patients will be the primary efficacy population for review, or only that you guys could use that population in its analysis? I guess, could the label or FDA review documents still emphasize outcomes across all 125 patients?
Oh, well, it's a little bit I guess the way to describe it, when you agree on a statistical analysis plan to the FDA, it's super important, because when you write Module Five, that's the clinical module, and there's a lot of tables and percentages and all has to connect. Being able to go from 125 - 120 makes that a more coherent document. That being said, the FDA has asked us. Like they all, for all companies, multiple sensitivity analysis, right? There are probably at least a half a dozen sensitivity analysis, which we will provide to them. Then the FDA will make some decisions to what goes in and out, because they will review the data on their own. But I think the difference is, we would expect some change, but maybe it's instead of 120 at the end, it's 122 or 118.
Now we're in the right zip code at least, which makes a big difference for us to be able to execute, and also for us to be in a good dialogue with the FDA.
Got it. Okay. Makes sense. For those sensitivity analyses, any more specifics on that and what types of analyses you're doing?
I think you can kind of imagine, right? If you kind of look through BCG usage, different sort of patient populations, because what they want to do, particularly in open-label study, they want to have the most homogenous patient population that is representative of what the drug usage is. We have a pretty rigorous inclusion/exclusion criteria, but they want to check that across. We will work with the FDA to go through some of those things.
Got it. In the May update, six of 43 initial non-responders achieved CR after re-induction. Did FDA agree that post-re-induction responses can be included in CR at any time, and how will their DOR be calculated in the BLA?
They are treated like that 120 is one big bucket, and they are like that one. The difference with their DOR is for the patients that respond at the three-month timeframe, their DOR is measured effectively at month 15. For the patients that respond in cycle two at the six-month timeframe, their DOR is month 18. That is the only difference.
Got it. Okay. You have said multiple times that there is no defined FDA efficacy bar, and that the package is sufficient to file. Has FDA commented on or articulated any durability analysis as important to approvability?
Yeah, I think what's important, this whole concept of a bar is a bit of a Wall Street type thing, right? The reality is I've been to the FDA many times, and I don't want to speak for the FDA, but the FDA assesses all products on a risk-benefit basis, right? If you look at our product from a risk perspective, tolerability, we're trending towards best-in-class tolerability. The way to measure tolerability is the patients stay on drug, and do they take their drug on time? We have a 1% discontinuation rate and a 4% treatment interruption rate, where some products are over 40%. Then in terms of safety, detalimogene is not a virus, it's a non-viral gene therapy. It's a plasmid. Frankly, if it fell on our hands, probably nothing. We wouldn't do it, but nothing would happen.
They like the fact it's non-viral and it's safe for handling. So, there's the risk part. On the benefit part, if you look at the they weight the primary endpoint pretty significantly, and the primary endpoint at 56% is right in the middle of the approved agents. The key secondary point is a cluster of things in durability. If you had a product that had a 56% CR rate, but it only lasted, let's make it out two or three months you'd say, "Well, it's not a very useful product." But you can see, like our median duration is already 10.1. Confidence interval, we haven't hit the upper bound as yet. So, that's a product that works over time. And then, if you look at the other durability measures, which will be a cluster, 43% durability Kaplan-Meier, 24% 12-month landmark. So, it's a cluster of things.
Based on that, the FDA, in our dialogue with them, said, "This is a fileable package." If they say, "You're eligible to begin the filing," they're busy folks, right? They accept packages that they, I think they believe that they're going to review and eventually approve. We feel pretty confident about that.
Got it. Okay. You mentioned the nine patients who are pending durability assessments. Maybe talk about scenarios with how that could play out on your efficacy. Is that the only remaining item that needs to be completed for the clinical module for the BLA package, and has a final data lock been agreed upon?
Yeah. We're in terrific shape as it comes to the FDA filing. You remember there's five modules, right? Two are technical modules. Module three is the manufacturing module, which is the biggest, right? And that module is going to be finished and is ready to go. Module four is the preclinical module. That's been sitting on the shelf ready to go. Module five is the clinical module. Remember, the clinical module in this case, just to give people perspective, is probably one to fifth the size of the CMC module. The manufacturing module is the biggest thing, massive. Been an issue in this category. Within the clinical, we have the shells written. We have nine patients to go. They will have their durability assessments relatively soon. We have a process with the FDA where that'll get dropped in at the right time.
We're on track, filing by the end of this year, acceptance early next year, and we expect an approval by the end of 2027.
Got it. For those nine patients, I guess, do you anticipate that could impact results or?
Marginally.
Yeah.
Marginally, because if you look at these are nine patients. We're waiting their durability assessment. If you make it into the maintenance phase, 100% are durable. The probability that most of them or all of them are going to be durable is pretty high. The reality is, that change will be marginal.
Got it. Okay. Is process validation complete, and is the intended commercial process the same as the process used to manufacture pivotal study lots? If not, what comparability work has to be done?
Our commercial supply is sitting on the shelf, waiting for a great label and waiting for a trade name and to be packaged, right? We completed our PPQ validation runs. We've been in dialogue with the FDA through CDRP. I think we feel pretty good about our manufacturing. We're manufacturing at scale. The FDA has worked with us on making sure that the process is the process that we will be launching the product with. This is a huge advantage for us because our product being a non-viral plasmid gene therapy, we use four readily available ingredients. So, low-cost ingredients. Because it's non-viral, the handling costs are a lot less. At the end, that'll be a competitive advantage for us. Our cost of goods of the immunotherapies will be one of the lowest, and will get better with volume.
Got it. Let's talk about competitive positioning. Which competing profile creates the greatest commercial pressure, and in what patient segment does detalimogene win despite some competitors having better durability and overall CR outcomes?
Yeah, that's a fallacy that there's competitors. Competitors sort of suggest that there's a winner, one winner takes all. That's a total fallacy. We don't have competitors. There are complementary products here, because what is the real competitor? The real competitor is radical cystectomy. So radical cystectomy has a 100% CR rate, right? However, in our study, 93% of the patients that were eligible for radical cystectomy said, "No." Why? Terrible mortality, terrible morbidity. Once a patient decides that they don't want their bladder removed, they will take multiple lines of therapy. The challenge right now is the quality of those lines of therapy and the ease of use has been extremely difficult. The other thing you must remember is that this is cancer, but this is urological bladder cancer. Progresses at 20% over 10 years, so this is a journey.
The other thing you must remember is that of all the new products that are launched, all of them, there's about a 50% recurrence rate. So in one year, 50% of the patients need a new medicine. They don't progress much, but they need a new medicine. So sequencing is going to be the order of the day. And right now, when you think about sequencing, or in the future, you'll all just have the choice of some chemo agents, they'll have the choice of bacterial agents, and they'll have the choice of viral gene therapies. detalimogene will be the only non-viral plasmid-based gene therapy. So when a doctor doesn't want to use the same type of modality, they're going to want to change it up, and that's where detalimogene will have a special place in many of the practices.
But it also will have a special place in what I call the green field. The nice thing about detalimogene, it can be used if you are in the forest of Wisconsin or if you're here at the Royal Marsden, you can use our product, because you don't need any special equipment, you don't need any special fridges, you don't need any special staff, right? And so there are a number of urologists that can't access these new medicines, and that detalimogene would be the first product that would be viable for them.
Got it. And kind of a theoretical question, but most responses occur by three months, but 44% of patients never achieve CR. Is there a clinical cost of delaying another therapy or cystectomy in those patients?
I think when I cited the number of a 3% progression rate, very little cost, right? So if you think about the risk-benefit of starting a new patient for a doctor, they literally, one of their staff can reach in the fridge or freezer, the regular fridge or the freezer where your ice cream is, or your fridge where your eggs are, mix with water, instill the patient. In the clinical study, they have to stay there for an hour, but now they could go home, right? And no pre-washes, no special equipment. You'll know within three months if it works, and if it doesn't work, there's only a 3% chance of progression. So actually, the hurdle rate to start detalimogene early is pretty low relative to other products.
Yeah. Makes sense. Let's talk about the commercial opportunity. You've mentioned $1 billion estimate for 2,000 patients, which implies $500,000 annual net revenue per patient. Can you talk about underlying assumptions on price, number of doses, and treatment persistence in the context of the demonstrated 10.1 months median DOR?
Yeah. I think for us, right now, we're continuing to look at the marketplace, continuing to do our forecast. But just to give you orders of magnitude, if you look at the price point, it's moved from about $250 to $500 to $700 per patient per- year. We've had some extensive market research with payers. As long as you have NCCN Category 2A guidelines, products are getting reimbursed. When we talk to urologists, they say, "Because it's cancer." This is a price, there seems to be relatively low price sensitivity. Now, we'll make our pricing decision at the very end, once we have our label, and to see what the competitive dynamic is. But if you then look at that, it takes only about 2,000 patients to hit $1 billion .
When you think there's about 20,000 to 40,000 patients, depending how you define the patient population, you can see that all these products could be very big products.
Got it.
as the market grows.
Maybe briefly talk about the surfactant. What do you want to see in efficacy there to give you confidence that it's actually different and you're not just seeing a variable result on that?
Well, I think for us, if you look at other viral gene therapies in their preclinical models, if they don't use a surfactant bladder rinse to scrape out the outside layer, they get very little transfection or no transfection. When they add a surfactant, it boosts things. Now, for detalimogene in our preclinical models, without a surfactant bladder rinse, we still get very good transfection. But when we add a surfactant bladder rinse, we get almost a 10 times increase in transfection. So we started a cohort of patients where we've gone through the safety run-in of patients, and we're enrolling that patient group. To me, what does a win look like? Win number one is if we can stay at 56% where we are now, CR any time, because we've reduced the dwell time from an hour to half an hour.
For these older patients, it's hard to hold it in. Then anything from an efficacy or durability on top of that will be a bonus as well. So it's a really great life cycle management play.
Got it. Ron, we're out of time. Exciting times ahead with focusing on the BLA for you guys. Maybe in closing, if you want to highlight the cash position and key catalysts ahead of that.
Exciting time for us. Each quarter, something good is going to happen. We plan to initiate the filing by the end of this year the BLA. It'll be accepted early next year. The surfactant data, we'll get data peek with 20-odd patients, plus or minus, mid-next year. Approval by the end of 2027. J-code in 2028. We're sitting with $246 million cash, enough money to do all that and more.
Got it. Thanks so much for joining us today, Ron.
Real pleasure. Thank you.